(Q38086651)

30 June 2019

title

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines (English)

1 reference

30 June 2019

1 reference

1

Jeffrey L Cummings

1 reference

30 June 2019

3

Martin Farlow

1 reference

30 June 2019

author name string

David Geldmacher

2

1 reference

30 June 2019

Marwan Sabbagh

4

1 reference

30 June 2019

Daniel Christensen

5

1 reference

30 June 2019

Peter Betz

6

1 reference

30 June 2019

language of work or name

1 reference

6 March 2013

1 reference

30 June 2019

CNS Neuroscience & Therapeutics

published in

1 reference

30 June 2019

volume

19

1 reference

30 June 2019

issue

5

1 reference

30 June 2019

page(s)

294-301

1 reference

30 June 2019

Alzheimer Disease in the US Population

cites work

1 reference

Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.

21 January 2018

1 reference

Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates

21 January 2018

1 reference

Predictors of nursing home admission for persons with dementia.

21 January 2018

1 reference

Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients.

21 January 2018

1 reference

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

21 January 2018

1 reference

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

21 January 2018

1 reference

Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.

21 January 2018

1 reference

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

21 January 2018

1 reference

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

21 January 2018

1 reference

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

21 January 2018

1 reference

Economic evaluation of donepezil in moderate to severe Alzheimer disease

21 January 2018

1 reference

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial

21 January 2018

1 reference

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

21 January 2018

1 reference

Alzheimer's failure raises questions about disease-modifying strategies

21 January 2018

1 reference

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology

21 January 2018

1 reference

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease

21 January 2018

1 reference

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine

21 January 2018

1 reference

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

21 January 2018

1 reference

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

21 January 2018

1 reference

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease

21 January 2018

1 reference

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

21 January 2018

1 reference

Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.

21 January 2018

1 reference

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial

21 January 2018

1 reference

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

Measuring cognition in advanced Alzheimer's disease for clinical trials

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23462265

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23462265

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/CNS.12076

1 reference

30 June 2019

PMC publication ID

6493345

1 reference

30 June 2019

PubMed publication ID

23462265

1 reference

30 June 2019